Investments in R&D Activities and Strong Product Sales Strengthen Companies' Financial Positions - Research Report on Alexion, Amgen, Vertex, Aegerion, and Acadia PR Newswire NEW YORK, August 2, 2013 NEW YORK, August 2, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), and ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Alexion Pharmaceuticals, Inc. Research Report On July 25, 2013, Alexion Pharmaceuticals Inc. (Alexion) reported its Q2 2013 financial results. The Company reported that its net products sales of Soliris (eculizumab) were $370.1 million, an increase of 34.7% YoY, in Q2 2013. The Company's GAAP net income for the quarter totaled $95.9 million or $0.48 per diluted share, compared to $36.3 million or $0.18 per diluted share in Q2 2012. "In the second quarter, we continued our strong and ongoing global performance with Soliris in PNH. In the early stages of our aHUS launch, we were especially pleased to provide Soliris to a steadily growing number of patients in the US and increasingly in Europe," said Leonard Bell, M.D., Chief Executive Officer of Alexion. Bell added, "As we enter the second half of the year, we will continue to develop our product portfolio toward supporting an anticipated series of significant launches in new indications for Soliris and new products over the next several years." Further, Alexion anticipates its full-year 2013 revenue to range between $1.52 billion and $1.53 billion, followed by non-GAAP EPS range of $2.97 and $3.02. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4619_ALXN] Amgen Inc. Research Report On July 30, 2013, Amgen Inc. (Amgen) reported its Q2 2013 financial results. The Company posted a revenue growth of 4.5% YoY to $4.7 million, followed by an adjusted EPS increase of 3.3% YoY to $1.89, in Q2 2013. Meanwhile, adjusted net income grew 0.8% YoY to $1.4 million during the quarter. "We saw solid product trends during the second quarter and are carrying good momentum into the second half," said Robert A. Bradway, Chairman and Chief Executive Officer at Amgen. "We continue to make excellent progress with our pipeline of innovative molecules and look forward to multiple data readouts in 2014, including pivotal Phase 3 data for our cholesterol-lowering agent, AMG 145, in the first quarter." For full-year 2013, the Company anticipates total revenues to range between $17.8 billion and $18.2 billion and adjusted EPS to be in the range of $7.30 to $7.45. The Full Research Report on Amgen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e96b_AMGN] Vertex Pharmaceuticals Incorporated Research Report On July 29, 2013, Vertex Pharmaceuticals Inc. (Vertex) reported its Q2 2013 financial results. The Company's revenues totaled $310.8 million during the quarter, down compared to $418.3 million in Q2 2012. GAAP net loss was $57.2 million or $0.26 per share in Q2 2013, compared to net loss of $64.9 million or $0.31 per diluted share in Q2 2012. "Entering the second half of 2013, we continue to progress key programs in cystic fibrosis, hepatitis C and rheumatoid arthritis and have strengthened our financial position to support continued investment in our business," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "Our progress in the first half of the year was marked by the initiation of a Phase 3 program in CF for people with the most common form of the disease, continued progress in bringing KALYDECO to people with CF around the world and the initiation of all-oral studies for VX-135 in hepatitis C." Further, Vertex updated its full-year 2013 revenues guidance to a range between $1.1 billion and $1.2 billion. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e696_VRTX] Aegerion Pharmaceuticals, Inc. Research Report On July 30, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) reported its Q2 2013 financial results. Net loss for the quarter was $18.9 million, or $0.66 per share, compared with net loss of $13.9 million, or $0.63 per share, in Q2 2012. Aegerion's R&D expenses increased to $7.6 million in Q2 2013 from $5.4 million in Q2 2012, driven by increased employee costs related to the Company's medical affairs and international regulatory activities, as well as increased clinical development expenses. "We continue to execute on launch, advancing early market uptake, and we see significant room for continued growth as we calibrate our activities surrounding the launch of JUXTAPID in the U.S.," said Marc D. Beer, Chief Executive Officer. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/a3f6_AEGR] ACADIA Pharmaceuticals, Inc. Research Report On July 30, 2013, Acadia Pharmaceuticals Inc. (Acadia) announced that it will release its Q2 2013 unaudited financial results on August 6, 2013, after the US financial markets close. Acadia's management will host a conference call and webcast on the same day at 5:00 p.m. ET, to discuss its financial results and development programs. The conference call will be webcast live on ACADIA's website and will be archived there until August 20, 2013. The Full Research Report on ACADIA Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3eb7_ACAD] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Investments in R&D Activities and Strong Product Sales Strengthen Companies' Financial Positions - Research Report on Alexion,
Press spacebar to pause and continue. Press esc to stop.